Institutional Biosafety Committee (IBC)
New electronic IBC (eIBC) launches June 13!
We are pleased to introduce the new electronic
Institutional Biosafety Committee (IBC) submission system which allows a direct
interface between the IBC and the researchers, electronic approval information,
real time access to forms and protocol information, and tracking of approval
status. Please refer to the FAQs about eIBC and the transfer to eIBC.
The NIH Guidelines Involving Recombinant or Synthetic Nucleic Acid Molecules, defines these nucleic acid molecules as:
(i) molecules that (a) are constructed by joining nucleic acid molecules and b) that can replicate in a living cell, i.e., recombinant nucleic acids;
(ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules, i.e. synthetic nucleic acids, or
(iii) molecules that result from the replication of those described in (i) or (ii) above.
Infectious Agents are generally defined as risk group 2 agents and above (agents that can cause disease in healthy adult humans).
Use of Biologically Derived Toxins need only be reviewed by the IBC if the toxin is a select agent, or if the toxin is lethal for vertebrates at an LD50 of less than 100 nanograms per kilogram body weight